- Home
- SPHL vs APVO Comparison
SPHL vs APVO Comparison
Compare SPHL & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHL
- APVO
- Stock Information
- Founded
- SPHL 2002
- APVO 2016
- Country
- SPHL Singapore
- APVO United States
- Employees
- SPHL N/A
- APVO N/A
- Industry
- SPHL Homebuilding
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- SPHL Consumer Discretionary
- APVO Health Care
- Exchange
- SPHL Nasdaq
- APVO Nasdaq
- Market Cap
- SPHL 4.9M
- APVO 4.1M
- IPO Year
- SPHL 2024
- APVO N/A
- Fundamental
- Price
- SPHL $0.37
- APVO $1.61
- Analyst Decision
- SPHL
- APVO Strong Buy
- Analyst Count
- SPHL 0
- APVO 1
- Target Price
- SPHL N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- SPHL 48.9K
- APVO 162.7K
- Earning Date
- SPHL 01-01-0001
- APVO 11-06-2025
- Dividend Yield
- SPHL N/A
- APVO N/A
- EPS Growth
- SPHL N/A
- APVO N/A
- EPS
- SPHL N/A
- APVO N/A
- Revenue
- SPHL $6,456,601.00
- APVO N/A
- Revenue This Year
- SPHL N/A
- APVO N/A
- Revenue Next Year
- SPHL N/A
- APVO N/A
- P/E Ratio
- SPHL N/A
- APVO N/A
- Revenue Growth
- SPHL N/A
- APVO N/A
- 52 Week Low
- SPHL $0.35
- APVO $1.54
- 52 Week High
- SPHL $7.80
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- SPHL 35.76
- APVO 28.32
- Support Level
- SPHL $0.39
- APVO $1.56
- Resistance Level
- SPHL $0.48
- APVO $1.73
- Average True Range (ATR)
- SPHL 0.06
- APVO 0.14
- MACD
- SPHL -0.01
- APVO 0.02
- Stochastic Oscillator
- SPHL 2.25
- APVO 11.29
About SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.